The Valley Desk

ArticleJournal of the American Academy of DermatologyPublished

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Journal of the American Academy of Dermatology
Published
Subject terms
Psoriasis; Adults; Withdrawal; Retreatment; Responder; Oral Peptide; Icotrokinra; Iconic-lead
PubMed ID
42176706
Added to directory
Source checked

Report a correction or request removal